## **Cornelis Kramers**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/190576/publications.pdf

Version: 2024-02-01

567281 454955 39 941 15 30 citations h-index g-index papers 41 41 41 1386 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Safety of ibogaine administration in detoxification of opioidâ€dependent individuals: a descriptive openâ€label observational study. Addiction, 2022, 117, 118-128.	3.3	20
2	RYR1-Related Rhabdomyolysis: A Spectrum of Hypermetabolic States Due to Ryanodine Receptor Dysfunction. Current Pharmaceutical Design, 2022, 28, 2-14.	1.9	11
3	The European Prescribing Exam: assessing whether European medical students can prescribe rationally and safely. European Journal of Clinical Pharmacology, 2022, 78, 1049-1051.	1.9	7
4	Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort. Diabetic Medicine, 2021, 38, e14406.	2.3	15
5	Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy. Journal of Antimicrobial Chemotherapy, 2021, 76, 212-219.	3.0	9
6	Prior use of therapeutic anticoagulation does not protect against COVIDâ€19 related clinical outcomes in hospitalized patients: A propensity scoreâ€matched cohort study. British Journal of Clinical Pharmacology, 2021, 87, 4839-4847.	2.4	21
7	European List of Essential Medicines for Medical Education: a protocol for a modified Delphi study. BMJ Open, 2021, 11, e045635.	1.9	5
8	Response to Luz & Mash on cardiac toxicity of ibogaine. Addiction, 2021, , .	3.3	0
9	Effects of Vitamin D and K on Interleukin-6 in COVID-19. Frontiers in Nutrition, 2021, 8, 761191.	3.7	11
10	Co-trimoxazole induced hyperkalemia and potassium monitoring in hospitalized patients. International Journal of Clinical Pharmacy, 2020, 42, 1405-1411.	2.1	0
11	HyperCKemia and rhabdomyolysis in the neuroleptic malignant and serotonin syndromes: A literature review. Neuromuscular Disorders, 2020, 30, 949-958.	0.6	9
12	Co-trimoxazole induced hyperkalemia and potassium monitoring in hospitalized patients. International Journal of Clinical Pharmacy, 2020, 42, 965-971.	2.1	1
13	Tackling rising numbers of opioid prescriptions users. Lancet Public Health, The, 2020, 5, e139.	10.0	2
14	Discontinuation of antidepressant medication in primary care supported by monitoring plus mindfulness-based cognitive therapy versus monitoring alone: design and protocol of a cluster randomized controlled trial. BMC Family Practice, 2019, 20, 105.	2.9	9
15	Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. Lancet Public Health, The, 2019, 4, e498-e505.	10.0	134
16	Mortality risk in atrial fibrillation: the roleÂof aspirin, vitamin K and non-vitamin K antagonists. International Journal of Clinical Pharmacy, 2019, 41, 1536-1544.	2.1	4
17	Towards a "prescribing license―for medical students: development and quality evaluation of an assessment for safe prescribing. European Journal of Clinical Pharmacology, 2019, 75, 1261-1268.	1.9	9
18	Delayed complications after severe clozapine intoxication. International Clinical Psychopharmacology, 2019, 34, 269-272.	1.7	5

#	Article	IF	Citations
19	Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring. Drug Safety, 2018, 41, 655-664.	3.2	7
20	QTc prolongation during erythromycin used as prokinetic agent in ICU patients. European Journal of Hospital Pharmacy, 2018, 25, 118-122.	1.1	11
21	Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer. Journal of Pain and Symptom Management, 2018, 55, e6-e8.	1.2	7
22	Clinical Relevance of Differences in Glomerular Filtration Rate Estimations in Frail Older People by Creatinine-vs. Cystatin C-Based Formulae. Drugs and Aging, 2017, 34, 445-452.	2.7	8
23	Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?. British Journal of Clinical Pharmacology, 2017, 83, 2356-2366.	2.4	31
24	Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 843-857.	3.3	17
25	Effects of Treating Primary Aldosteronism on Renal Function. Journal of Clinical Hypertension, 2017, 19, 290-295.	2.0	28
26	Metamizole (Dipyrone) as an Alternative Agent in Postoperative Analgesia in Patients with Contraindications for Nonsteroidal Antiâ€Inflammatory Drugs. Pain Practice, 2017, 17, 402-408.	1.9	57
27	Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial. Journal of Psychopharmacology, 2017, 31, 184-191.	4.0	41
28	Safe use of NSAIDs and RAS-inhibitors at Agogo Presbyterian Hospital, Ghana. Ghana Medical Journal, 2016, 50, 22.	0.4	0
29	Potentially inappropriate prescribing in older patients admitted to psychiatric hospital. International Journal of Geriatric Psychiatry, 2016, 31, 137-145.	2.7	33
30	Drug therapy management in patients with renal impairment: how to use creatinine-based formulas in clinical practice. European Journal of Clinical Pharmacology, 2016, 72, 1433-1439.	1.9	20
31	P1-297: Efficacy and safety of delta-9-tetrahydrocannabinol in behavioral disturbances in dementia: A randomized controlled trial., 2015, 11, P469-P470.		7
32	Timeâ€trends in the prescribing of gastroprotective agents to primary care patients initiating lowâ€dose aspirin or nonâ€steroidal antiâ€inflammatory drugs: a populationâ€based cohort study. British Journal of Clinical Pharmacology, 2015, 80, 589-598.	2.4	16
33	Individualizing Pharmacotherapy in Patients with Renal Impairment: The Validity of the Modification of Diet in Renal Disease Formula in Specific Patient Populations with a Glomerular Filtration Rate below 60 Ml/Min. A Systematic Review. PLoS ONE, 2015, 10, e0116403.	2.5	10
34	NSAID–antihypertensive drug interactions: Which outpatients are at risk for a rise in systolic blood pressure?. European Journal of Preventive Cardiology, 2015, 22, 91-99.	1.8	11
35	Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology, 2015, 232, 2587-2595.	3.1	59
36	Tetrahydrocannabinol for neuropsychiatric symptoms in dementia. Neurology, 2015, 84, 2338-2346.	1.1	118

#	Article	IF	CITATIONS
37	Efficacy and safety of medical cannabinoids in older subjects: A systematic review. Ageing Research Reviews, 2014, 14, 56-64.	10.9	97
38	Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: A randomized controlled trial. European Neuropsychopharmacology, 2014, 24, 1475-1482.	0.7	49
39	Cannabis Coadministration Potentiates the Effects of "Ecstasy―on Heart Rate and Temperature in Humans. Clinical Pharmacology and Therapeutics, 2009, 86, 160-166.	4.7	41